{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:34:39Z","timestamp":1778272479124,"version":"3.51.4"},"reference-count":31,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2004,4,22]],"date-time":"2004-04-22T00:00:00Z","timestamp":1082592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:p><jats:bold>Aims\u2002<\/jats:bold> Treatment with vitamin D sterols can lower plasma parathyroid hormone (PTH) in patients with secondary hyperparathyroidism; however, hypercalcaemia, hyperphosphataemia, or both, often develop. Calcimimetic agents, employed in alternative therapeutic approaches, directly inhibit PTH secretion by activating the calcium\u2010sensing receptor in the parathyroid glands.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> In this study, patients were given orally 25, 50, and 100\u2003mg doses of the calcimimetic agent KRN 1493 each on two occasions, on the day of haemodialysis and on the day without haemodialysis.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> In the pharmacokinetic results, because the clearance of KRN 1493 by haemodialysis was much smaller than the systemic clearance, the influence of haemodialysis was not remarkable. In the pharmacodynamic study, on both the days with or without haemodialysis, plasma PTH concentrations decreased in a dose\u2010dependent manner. Serum calcium concentrations decreased in association with the decrease in plasma PTH concentrations. Mild dose\u2010dependent adverse effects (mainly nausea) were seen after the administration of KRN 1493 on both the day of haemodialysis and the day without haemodialysis.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> We conclude that the pharmacokinetics of KRN 1493 after a single administration were similar on the day of haemodialysis and the day without haemodialysis. KRN 1493 is safe and effective in suppressing PTH secretion and serum calcium concentrations on the day of haemodialysis and on the day without haemodialysis in patients with secondary hyperparathyroidism.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2004.02088.x","type":"journal-article","created":{"date-parts":[[2004,5,18]],"date-time":"2004-05-18T16:04:33Z","timestamp":1084896273000},"page":"726-734","source":"Crossref","is-referenced-by-count":33,"title":["The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis"],"prefix":"10.1111","volume":"57","author":[{"given":"Naro","family":"Ohashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Uematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsutaka","family":"Kanamaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akashi","family":"Togawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Hishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shozo","family":"Koshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,4,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.07304.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1001\/archinte.1969.00300200043008","article-title":"Secondary hyperparathyroidism in chronic renal failure","volume":"124","author":"Massry SG","year":"1969","journal-title":"Arch Intern Med"},{"key":"e_1_2_6_4_2","first-page":"219","article-title":"Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia","volume":"14","author":"Massry SG","year":"1994","journal-title":"Semin Nephrol"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.00575.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(97)90484-4"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v31.pm9531176"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.290.6464.271"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1993.64"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198908033210502"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00045.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19\u2010Nor\u20101\u2010\u03b1\u201025\u2010dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of PTH in patients with hemodialysis","volume":"9","author":"Martin KJ","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.0590031187.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(97)90009-3"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(97)90352-8"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.07307.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(00)70064-3"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-56-3-572"},{"key":"e_1_2_6_19_2","first-page":"1083","article-title":"Allosteric activation of the calcium receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568","volume":"53","author":"Hammerland LG","year":"1998","journal-title":"Mol Pharmacol"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.7.4040"},{"key":"e_1_2_6_21_2","first-page":"1019","volume-title":"Principles in Bone Biology","author":"Nemeth EF.","year":"1996"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119851"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00782.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00837.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.2.204"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The calcimimetic agent AMG 073 lowers parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Goodman WG","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00720.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum phosphorus, calcium x phosphorus product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh SK","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.07316.x"},{"key":"e_1_2_6_30_2","first-page":"81","volume-title":"Metabolic bone diseases and disorders of mineral metabolism","author":"Juppner H","year":"1999"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00735.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-125-1-275"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2004.02088.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2004.02088.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T23:19:15Z","timestamp":1697239155000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2004.02088.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,22]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1111\/j.1365-2125.2004.02088.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02088.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,22]]}}}